381 related articles for article (PubMed ID: 27984060)
1. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
[TBL] [Abstract][Full Text] [Related]
3. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.
El-Tahan RR; Ghoneim AM; Zaghloul H
Virus Genes; 2020 Oct; 56(5):564-581. PubMed ID: 32572756
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
Gaudieri S; Rauch A; Pfafferott K; Barnes E; Cheng W; McCaughan G; Shackel N; Jeffrey GP; Mollison L; Baker R; Furrer H; Günthard HF; Freitas E; Humphreys I; Klenerman P; Mallal S; James I; Roberts S; Nolan D; Lucas M
Hepatology; 2009 Apr; 49(4):1069-82. PubMed ID: 19263475
[TBL] [Abstract][Full Text] [Related]
6. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
Sun D; Dai M; Shen S; Li C; Yan X
Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT
Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675
[TBL] [Abstract][Full Text] [Related]
11. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
Coppola N; Minichini C; Starace M; Sagnelli C; Sagnelli E
J Med Virol; 2016 Oct; 88(10):1659-71. PubMed ID: 26991255
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
20. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
